Dec 19 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING.AERIE PHARMACEUTICALS - PURSUANT TO AGREEMENT, CO MAY OFFER AND SELL SHARES, PAR VALUE $0.001 PER SHARE, HAVING OFFERING PRICE OF UP TO $75 MILLION.
Full Article
Dec 18 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE LOWERING OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - REMAIN ON TRACK TO FILE ROCLATAN NEW DRUG APPLICATION TO FDA IN Q2 2018.AERIE PHARMACEUTICALS - RHOPRESSA APPROVED AHEAD OF SCHEDULED PDUFA DATE OF FEBRUARY 28, 2018.
Full Article
Nov 16 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan.Aerie Pharmaceuticals Inc - for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018.
Full Article
Nov 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 adjusted loss per share $0.71.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Q3 gaap loss per share $0.89.Aerie Pharmaceuticals Inc - as of september 30, 2017, Aerie had $282.2 million in cash, cash equivalents and investments.
Full Article
Oct 13 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct.
Full Article
May 25 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals - on May 25, co entered into controlled equity offering sales agreement with Cantor Fitzgerald & Co. - SEC filing.Aerie Pharmaceuticals - under agreement co may offer and sell shares of common stock, having an aggregate offering price of up to $50 million.
Full Article
May 24 (Reuters) - Aerie Pharmaceuticals Inc :Aerie pharmaceuticals reports positive roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 topline efficacy results.Aerie pharmaceuticals inc - roclatan™ successfully achieves primary efficacy endpoint in mercury 2 study.Aerie pharmaceuticals inc - if mercury 1 12-month safety results are also successful, we expect to submit roclatan nda in first half of 2018.
Full Article
Aerie Pharmaceuticals Inc : Expects cash and cash equivalents to total approximately $230 million as of December 31, 2016 . Updated full-year 2016 cash burn guidance to approximately $85 million, an increase from previous guidance of $75 million .Updated guidance reflects initiatives like start-up of clinical trials in Japan, construction of manufacturing plant in Ireland.
Full Article
Aerie Pharmaceuticals Inc :Submits new drug application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02 percent.
Full Article
Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals reports second quarter 2016 financial results and provides business update . Q2 GAAP loss per share $0.87 . Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S . Q2 adjusted loss per share $0.72 .Aerie Pharmaceuticals Inc says remains on track to file its NDA for Rhopressa(TM)(Netarsudil Ophthalmic Solution) 0.02% in Q3 of 2016.
Full Article
Earnings vs. 
Estimates